Developing personalized algorithms to identify cancer-specific neoantigens
Beyond Binding: Personalized Multi-omic Neoantigen Identification
This study is working on a new way to make cancer treatment more effective by using personalized immunotherapy that targets specific markers in your tumor, and it's designed to help patients by improving how we identify these markers and activate the immune system.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-11108130 on NIH RePORTER |
What this research studies
This research focuses on improving cancer treatment through personalized neoantigen immunotherapy by creating a more accurate prediction algorithm that integrates multiomic data. It aims to address the challenges of selecting and validating neoantigens, which are crucial for effective immunotherapy. By utilizing a diverse dataset of tumor and normal specimens, the project seeks to enhance the precision of neoantigen identification and T cell activation. The approach includes advanced algorithm development and the use of innovative assays to ensure better outcomes for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients who have diverse HLA alleles and are seeking personalized immunotherapy options.
Not a fit: Patients with cancers that do not respond to neoantigen-based therapies or those without suitable HLA alleles may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized cancer immunotherapies, improving treatment outcomes for patients.
How similar studies have performed: Other research has shown promise in using multiomic approaches for neoantigen identification, but this specific algorithm development is innovative and aims to address existing limitations.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Karchin, Rachel — Johns Hopkins University
- Study coordinator: Karchin, Rachel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.